Drug Profile
COM 902
Alternative Names: COM-902Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator Compugen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Colorectal cancer; Multiple myeloma; Solid tumours
Most Recent Events
- 03 Oct 2023 Compugen has patent protection for "Triple Combination Antibodies Therapies" in Japan
- 28 Apr 2023 Phase-I development in Multiple-myeloma and Solid tumours is ongoing in USA (Parenteral) (NCT04354246)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral)